• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Editor's Pick

Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

by October 2, 2025
written by October 2, 2025

Sen. Josh Hawley, R-Mo., accused the Food and Drug Administration (FDA) of endangering women’s health, saying the agency approved another chemical abortion drug without the thorough safety review it had promised.

Hawley argued the move shows both regulatory failure and the influence of a company that refuses to define ‘woman’ in its materials.

‘This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,’ he wrote on X on Thursday afternoon.

Hawley added, ‘FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA.’

Evita Solutions describes its mission as to ‘normalize abortion’ and make it ‘accessible to all.’ On its website, the company says it ‘believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.’

It adds, ‘We know that you can make the best choice for your body.’

According to the FDA, Evita received approval in a Sept. 30 letter obtained by Reuters.

In an interview with Fox News Digital, Hawley said the FDA’s decision was even more troubling given that its promised safety review has barely begun.

‘I just, I can’t figure out what’s happening at the FDA. I’m totally baffled by it,’ Hawley said.

Fox News Digital has reached out to the FDA and Evita Solutions for comment on the matter.

In another post, Hawley blasted the FDA for partnering with a company that ‘doesn’t even believe there is such a thing as a ‘woman.’’

Evita Solutions now joins GenBioPro in producing the generic version of Mifepristone, the abortion pill originally made by Danco Laboratories. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the process.

The approval comes as abortion drugs face mounting opposition from conservative lawmakers, religious organizations, and pro-life groups.

Religious groups like Inspire Investing and Alliance Defending Freedom have campaigned against the drug, while the Restoration of America Foundation (ROAF) has pressed lawmakers for accountability.

Last month, ROAF called on the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable at a hearing, demanding answers about the removal of safety protocols for the abortion pill Mifepristone.

In a letter obtained by Fox News Digital, ROAF warned that the rollback leaves women more vulnerable and shifts costs to taxpayers. The group said the Biden-era changes endanger women by allowing abortion pills to be prescribed via telehealth and sent through the mail.

Hawley said the FDA should restore the safeguards put in place under the Trump administration.

‘What needs to happen is the FDA needs to get in line with the president’s policy and put back into place the safety regulations President Trump had. Ditch the Biden approach and go back to President Trump’s approach,’ Hawley said.

Under the Biden administration, the FDA for the first time allowed telehealth prescribing and mail-order delivery of abortion pills. Previously, the agency required Mifepristone to be dispensed in person to screen for complications such as ectopic pregnancy.

Fox News Digital’s Jasmine Baehr and Reuters contributed to this report.

This post appeared first on FOX NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
The agency staff Vought might recommend cutting and whether the cuts will be permanent

related articles

Trump’s DOGE savings dwarfed by Medicare, Social Security...

October 2, 2025

FLASHBACK: James Comey urged officials to always prosecute...

October 2, 2025

The agency staff Vought might recommend cutting and...

October 2, 2025

Reagan-appointed judge, once rebuked by Supreme Court, continues...

October 2, 2025

‘Real consequences’: Food aid, flood insurance, FEMA funds...

October 2, 2025

Trump must triple severely outdated nuke arsenal to...

October 2, 2025

White House says federal layoffs could hit ‘thousands’...

October 2, 2025

Johnson shuts door on negotiating shutdown deal as...

October 2, 2025

Democrats refuse to budge over Obamacare fight as...

October 2, 2025

War Department pushes back on ‘false’ narrative of...

October 2, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Robinhood CEO sees Amazon-like subscription model as path to ‘loyalty’ in financial services

    March 28, 2025
  • Mutiny threat sparks House GOP infighting ahead of Trump visit: ‘Just more stupid’

    November 13, 2024
  • House Republicans clear path for Trump to act on tariff plans

    January 24, 2025
  • Morning Glory: Justice Gorsuch takes his case public

    August 6, 2024
  • Trump taps Brooke Rollins as agriculture secretary

    November 23, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (6,247)
  • Investing (634)
  • Stock (935)

Latest Posts

  • ‘Shirts and Skins’: How one Republican bridged the gap to pass Trump’s ‘big, beautiful bill’

    July 24, 2025
  • 10 questions that should haunt Democrats this Election Day

    November 4, 2024
  • US hits ISIS camps in Syria, killing nearly 3 dozen terrorists

    October 30, 2024

Recent Posts

  • From Zapruder to smartphones: Assassination footage reshapes America’s view of political violence

    September 14, 2025
  • ‘I didn’t know that’: Musk surprises Trump with revelation about his 2024 endorsement

    February 19, 2025
  • Supreme Court flare-ups grab headlines as justices feel the heat

    May 6, 2025

Editor’s Pick

  • EURUSD and GBPUSD: New week, new targets and prices

    October 7, 2024
  • Russian drone strikes kill 7 in Kharkiv during Zelenskyy’s White House meeting with Trump

    August 18, 2025
  • Trump’s hostage envoy Boehler met with Taliban in Kabul in first in-person meeting since takeover

    March 21, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock